MSU Sponsors
Learn More About Our Sponsors
argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating product candidates in multiple serious autoimmune diseases and advancing several early stage experimental medicines within a number of therapeutic franchises. For more information, visit argenx and follow us on LinkedIn, Twitter, and Instagram.
Priovant
Our Mission:
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies. You can read more about our work here.
EMD Serono
At EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., we work to transform lives by developing and delivering meaningful therapies, and working to truly understand and respond to the therapeutic and support needs of individual patients.
Abcuro
Abcuro is developing its lead product candidate ABC008 for autoimmune disorders and rare cancers, including inclusion body myositis (IBM), T Cell Large Granular Lymphocytic Leukemia (T-LGLL) and T and NK cell lymphomas. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting killer cell lectin-like receptor G1 (KLRG1), a marker selectively expressed on these highly cytotoxic T cells.
In IBM and T-LGLL, cytotoxic T cells are a major source of chronic tissue damage. For mature T and NK cell lymphomas, the KLRG1 expressing T cells or NK cells are malignant. In November 2021, we presented initial results from a Phase 1 open-label trial of ABC008 in IBM at American College of Rheumatology Convergence 2021 (view poster) and an updated dataset was presented at GCOM 2022 (view poster). In this trial, ABC008 demonstrated potent depletion of KLRG1+ T cells in patients with IBM.
Cabaletta Bio
The Final Act for Autoimmune Disease
What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.
On a proven foundation of CAR T technology and an established track record of clinical operational excellence in cell therapy in autoimmunity since 2018, we are developing innovative engineered T cell therapies for patients with autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA®) platform is designed to provide deep, durable, and potentially curative responses with one-time administration across many autoimmune diseases, and it encompasses two approaches.
The Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach is designed to transiently, but fully, eliminate B cells, thus potentially enabling an “immune system reset.” Our lead CARTA candidate, CABA-201, is a fully human CD19-CAR T cell product candidate being evaluated in the RESETTM Phase 1/2 trials in autoimmune diseases with high unmet need, including in systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.
Cabaletta’s initial Chimeric AutoAntibody Receptor T (CAART) cell approach is designed to eliminate only disease-causing B cells. The DesCAARTes™ and MusCAARTes™ trials are underway in patients with mucosal-dominant pemphigus vulgaris and MuSK myasthenia gravis, respectively.
Our Mission
To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.
Sponsorship Opportunities Are Available
MSU is instrumental in improving the lives of people living with myositis (idiopathic inflammatory myopathies), a group of rare, complicated autoimmune muscle, skin, and often multi-organ diseases, through education, support, awareness, advocacy, access to research, and need-based financial assistance.
We are a fast-growing patient-led 501(c)(3) nonprofit organization with the experience needed to support and advocate for myositis patients and caregivers. Myositis affects the whole person and every aspect of their life. Understanding this disease isn’t limited to symptoms, we push for the inclusion of the patient voice in research and clinical care, and we work to empower the community to acknowledge patients and caregivers as equals – a part of a team – in their healthcare management.
We provide more than support. We continually work hard as an all-volunteer organization providing patient-centered programs and services and building unique and meaningful partnerships in the rare disease community. Technology is a driving force in our continued growth and success; educating, supporting, and connecting patients, caregivers, and family members with one another, and with doctors, researchers, clinical trials, partners, and patient-first focused providers.
Sponsorships include both our comprehensive myositis website, Understandingmyositis.org, and our #MyositisLIFE program and website; giving a voice to patients and caregivers.
#MyositisLIFE is our newest program with a dedicated interactive community-based website, and it provides a solution to a missing piece in awareness and research; the patient voice.
